Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03015402 · ClinicalTrials.gov registry record · Phase 2
Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
A Phase 2 study of Heart Failure and Pulmonary Hypertension Secondary, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03015402: Completed Phase 2 study of Heart Failure and Pulmonary Hypertension Secondary, sponsored by University of Pittsburgh.
NCT03015402 is a Phase 2 study of Heart Failure and Pulmonary Hypertension Secondary that has completed, run by University of Pittsburgh. The registered enrollment target is 33 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03015402, a Phase 2 study of Heart Failure and Pulmonary Hypertension Secondary, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objective of this study is to determine the clinical efficacy of oral inorganic nitrite verses placebo and the therapeutic response with regards to exercise tolerance in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).
Primary Outcome
Mean Pulmonary Artery Pressure measurement at submaximal exercise as compared between Placebo and Oral Nitrite at 10 weeks.
Conditions Studied
Interventions
- DRUG Placebo Oral Capsule
- DRUG Sodium Nitrite
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-10-30 |
| Est. Completion | 2023-01-25 |
| Phase | Phase 2 |
What the finished NCT03015402 record still lists
NCT03015402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT03015402 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03015402 about?
NCT03015402 is a clinical study titled "Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction". The main objective of this study is to determine the clinical efficacy of oral inorganic nitrite verses placebo and the therapeutic response with regards to exercise tolerance in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).
What is the current status of trial NCT03015402?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-10-30. Estimated completion is 2023-01-25.
What conditions does trial NCT03015402 study?
This clinical trial studies the following conditions: Heart Failure, Pulmonary Hypertension Secondary.
What interventions are being tested in trial NCT03015402?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Sodium Nitrite (DRUG).
Who is sponsoring clinical trial NCT03015402?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03015402 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03015402's enrollment target sits among peer trials
33 316th of 397 higher than 81 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI